Traders sold shares of Edwards Lifesciences Corp. (NYSE:EW) on strength during trading on Friday. $115.23 million flowed into the stock on the tick-up and $134.70 million flowed out of the stock on the tick-down, for a money net flow of $19.47 million out of the stock. Of all equities tracked, Edwards Lifesciences Corp. had the 0th highest net out-flow for the day. Edwards Lifesciences Corp. traded up $3.12 for the day and closed at $118.07

A number of research firms have recently issued reports on EW. Morgan Stanley restated a “buy” rating and issued a $140.00 price target on shares of Edwards Lifesciences Corp. in a research note on Friday. Evercore ISI restated a “hold” rating and issued a $115.00 price target on shares of Edwards Lifesciences Corp. in a research note on Friday. Leerink Swann restated a “buy” rating on shares of Edwards Lifesciences Corp. in a research note on Friday. Jefferies Group restated a “buy” rating and issued a $125.00 price target (up from $105.00) on shares of Edwards Lifesciences Corp. in a research note on Wednesday, April 27th. Finally, Deutsche Bank AG raised their price target on Edwards Lifesciences Corp. from $100.00 to $115.00 and gave the stock a “hold” rating in a research note on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $118.13.

The stock has a market capitalization of $25.13 billion and a PE ratio of 48.79. The stock’s 50 day moving average price is $109.57 and its 200 day moving average price is $99.30.

Edwards Lifesciences Corp. (NYSE:EW) last released its quarterly earnings results on Tuesday, July 26th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.06. The company had revenue of $759.30 million for the quarter, compared to analyst estimates of $724.26 million. During the same quarter last year, the company earned $0.57 EPS. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. Equities research analysts expect that Edwards Lifesciences Corp. will post $2.87 EPS for the current fiscal year.

In other Edwards Lifesciences Corp. news, VP Robert W.A. Sellers sold 10,000 shares of the stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $114.33, for a total value of $1,143,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 49,100 shares of the stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $102.75, for a total transaction of $5,045,025.00. Following the completion of the sale, the chief executive officer now owns 127,341 shares of the company’s stock, valued at approximately $13,084,287.75. The disclosure for this sale can be found here.

Other hedge funds have added to or reduced their stakes in the company. RS Investment Management Co. LLC increased its stake in Edwards Lifesciences Corp. by 77.6% in the fourth quarter. RS Investment Management Co. LLC now owns 168,325 shares of the medical research company’s stock worth $13,294,000 after buying an additional 73,540 shares during the last quarter. Utah Retirement Systems increased its stake in Edwards Lifesciences Corp. by 99.0% in the fourth quarter. Utah Retirement Systems now owns 38,536 shares of the medical research company’s stock worth $3,044,000 after buying an additional 19,168 shares during the last quarter. KBC Group NV increased its stake in Edwards Lifesciences Corp. by 279.9% in the fourth quarter. KBC Group NV now owns 130,931 shares of the medical research company’s stock worth $10,341,000 after buying an additional 96,462 shares during the last quarter. State of Tennessee Treasury Department increased its stake in Edwards Lifesciences Corp. by 47.3% in the fourth quarter. State of Tennessee Treasury Department now owns 90,877 shares of the medical research company’s stock worth $7,178,000 after buying an additional 29,177 shares during the last quarter. Finally, Birch Hill Investment Advisors LLC increased its stake in Edwards Lifesciences Corp. by 86.3% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 299,002 shares of the medical research company’s stock worth $23,615,000 after buying an additional 138,539 shares during the last quarter.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.